D-0756-2023 Class III Terminated

Recalled by Amneal Pharmaceuticals Of New York, LLC — Brookhaven, NY

FDA drug recall D-0756-2023 was initiated by Amneal Pharmaceuticals Of New York, LLC on May 8, 2023 and is designated Class III. Reason for recall: Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1… The recall status is terminated (terminated Mar 21, 2024). Affected quantity: 69,239 vials.

Recall details

Product Type
Drugs
Report Date
May 31, 2023
Initiation Date
May 8, 2023
Termination Date
Mar 21, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
69,239 vials

Product description

Methylprednisolone Acetate Injectable Suspension, USP 80 mg/mL, For Intramuscular, Intrasynovial and Soft Tissue Injection Only, Not for Intravenous Use, 1 mL Single Dose Vial, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Parenteral Unit, Ahmedabad 382213, India, Amneal Pharamceuticals LLC, Bridgewater, NJ 08807, NDC 70121-1574-01.

Reason for recall

Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1; Correct NDC Number 70121-1574-1.

Distribution pattern

Nationwide in the USA and PR

Code information

Lot Numbers: AP220481, Exp 09/2024; AP220536A, Exp 10/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0756-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0756-2023. Report a data issue: hello@regdatalab.com.